BiotechTube

Maxigesic® IV

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postoperative Pain

Conditions

Postoperative Pain

Trial Timeline

Jul 22, 2019 → Jul 7, 2020

NCT ID
NCT04005755

About Maxigesic® IV

Maxigesic® IV is a phase 3 stage product being developed by AFT Pharmaceuticals for Postoperative Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT04005755. Target conditions include Postoperative Pain.

What happened to similar drugs?

20 of 20 similar drugs in Postoperative Pain were approved

Approved (20) Terminated (3) Active (0)
✅Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVEisaiApproved
✅EsomeprazoleAstraZenecaApproved
✅Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, PlaceboMerckApproved
✅Sugammadex + NeostigmineMerckApproved
✅Aprepitant + Dexamethasone + Ondansetron + DexamethasoneMerckApproved
✅Suvorexant + PlaceboMerckApproved
✅Aprepitant plus Ondansetron + Ondansetron plus placeboMerckApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04005755Phase 3Completed

Competing Products

20 competing products in Postoperative Pain

See all competitors
ProductCompanyStageHype Score
Naldemedine + PlaceboShionogiPhase 2
27
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVEisaiApproved
43
Lemborexant 5 mg + Control (placebo) groupEisaiPhase 2
42
Ondansetron + PalonosetronEisaiPhase 2
35
AQUAVAN (fospropofol disodium; GPI 15715 )EisaiPhase 2
35
ONO-1101Ono PharmaceuticalPhase 2
35
ONO-1101Ono PharmaceuticalPhase 2/3
38
Levofloxacin Ophthalmic + CefuroximeSanten PharmaceuticalPhase 1/2
28
Levofloxacin Ophthalmic Product + Moxifloxacin Ophthalmic SolutionSanten PharmaceuticalPhase 1/2
28
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparationJiangsu Hengrui MedicinePhase 1
29
SHR0410 Injection + SHR0410 Injection + PlaceboJiangsu Hengrui MedicinePhase 3
36
SHR8554 InjectionJiangsu Hengrui MedicinePhase 1
29
EsomeprazoleAstraZenecaApproved
43
deep neuromuscular blockMerckPre-clinical
26
Rolapitant Dose 1 + Rolapitant Dose 2 + Rolapitant Dose 3 + Rolapitant Dose 4 + Ondansetron + PlaceboMerckPhase 2
35
MK0966, rofecoxib + Comparator: valdecoxibMerckPhase 3
40
Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, PlaceboMerckApproved
43
MK0719MerckPhase 2
27
Sugammadex + NeostigmineMerckApproved
43
MK0869, aprepitant + Comparator: ondansetron IVMerckPhase 3
40